Grossebrummel H, Peter T, Mandelkow R, Weiss M, Muzzio D, Zimmermann U, et al. Cytochrome P450 17A1 inhibitor abiraterone attenuates cellular growth of prostate cancer cells independently from androgen receptor signaling by modulation of oncogenic and apoptotic pathways. Int J Oncol. 2016;48:793-800 pubmed publisher

Crawford E, Higano C, Shore N, Hussain M, Petrylak D. Treating Patients with Metastatic Castration Resistant Prostate Cancer: A Comprehensive Review of Available Therapies. J Urol. 2015;194:1537-47 pubmed publisher

Ryan C, Smith M, Fong L, Rosenberg J, Kantoff P, Raynaud F, et al. Phase I clinical trial of the CYP17 inhibitor abiraterone acetate demonstrating clinical activity in patients with castration-resistant prostate cancer who received prior ketoconazole therapy. J Clin Oncol. 2010;28:1481-8 pubmed publisher

Reid A, Attard G, Danila D, Oommen N, Olmos D, Fong P, et al. Significant and sustained antitumor activity in post-docetaxel, castration-resistant prostate cancer with the CYP17 inhibitor abiraterone acetate. J Clin Oncol. 2010;28:1489-95 pubmed publisher

Danila D, Morris M, de Bono J, Ryan C, Denmeade S, Smith M, et al. Phase II multicenter study of abiraterone acetate plus prednisone therapy in patients with docetaxel-treated castration-resistant prostate cancer. J Clin Oncol. 2010;28:1496-501 pubmed publisher

Attard G, Reid A, Olmos D, de Bono J. Antitumor activity with CYP17 blockade indicates that castration-resistant prostate cancer frequently remains hormone driven. Cancer Res. 2009;69:4937-40 pubmed publisher

Attard G, Reid A, A Hern R, Parker C, Oommen N, Folkerd E, et al. Selective inhibition of CYP17 with abiraterone acetate is highly active in the treatment of castration-resistant prostate cancer. J Clin Oncol. 2009;27:3742-8 pubmed publisher